CELL THERAPEUTICS INC

Inactive Instrument

Analyst Reco. Cell Therapeutics Inc Nasdaq

Equities

US1509348835

End-of-day quote Nasdaq Other stock markets
- ^USD	-

2023	DRI Healthcare Trust Receives US$54.8 Million in Debt Repayment	MT
2023	DRI Healthcare Trust Brief: Announcing US$54.8 Million Debt Repayment from CTI BioPharma Corp.	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

SVB Securities Downgrades CTI BioPharma to Market Perform From Outperform, Adjusts Price Target to $9.10 From $13	23-05-16	MT
JMP Securities Downgrades CTI BioPharma to Market Perform From Market Outperform	23-05-11	MT
Needham Downgrades CTI BioPharma to Hold From Buy With $9 Price Target	23-05-11	MT
European shares edge higher as US CPI data looms, Credit Agricole gains	23-05-10	RE
TD Cowen Adjusts Price Target on CTI BioPharma to $8 From $10, Maintains Outperform Rating	23-04-17	MT
SVB Securities Starts CTI BioPharma at Outperform with $13 Price Target	22-10-17	MT
Jefferies Starts CTI BioPharma at Buy With $13 Price Target	22-09-01	MT
JMP Securities Adjusts CTI BioPharma Price Target to $9 From $6, Maintains Market Outperform Rating	22-08-09	MT
Cowen Starts CTI BioPharma at Outperform With $10 Price Target	22-07-07	MT
Needham Raises CTI BioPharma's Price Target to $8 From $5, Maintains Buy Rating	22-03-02	MT
JMP Securities Adjusts CTI BioPharma Price Target to $5 From $4, Maintains Market Outperform Rating	22-03-02	MT
Needham Adjusts Price Target on CTI BioPharma to $5 From $6, Maintains Buy Rating	21-12-01	MT
CTI BIOPHARMA : BTIG Starts CTI BioPharma at Buy With $7 Price Target	21-08-09	MT
CTI BIOPHARMA : Lake Street Adjusts Price Target on CTI BioPharma to $15 From $13, Maintains Buy Rating	21-06-01	MT
CTI BIOPHARMA : Stifel Initiates CTI BioPharma at Buy Rating With $5.50 Price Target	21-05-06	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019

Replicate our performance

fermer